Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,446JPY
2 May 2016
Change (% chg)

¥-52 (-3.44%)
Prev Close
¥1,497
Open
¥1,422
Day's High
¥1,450
Day's Low
¥1,415
Volume
8,751,400
Avg. Vol
8,248,125
52-wk High
¥2,009
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.66
Market Cap(Mil.): ¥3,211,646.00
Shares Outstanding(Mil.): 2,221.82
Dividend: 16.00
Yield (%): 2.21

Financials

  4503.T Industry Sector
P/E (TTM): 16.91 33.53 41.92
EPS (TTM): 85.48 -- --
ROI: 13.23 13.05 12.53
ROE: 13.77 13.77 13.43
Search Stocks

BRIEF-Astellas Pharma names Rodrigo Fernandez executive director, international business

* Astellas names Rodrigo Fernandez executive director, international business Source text for Eikon: Further company coverage:

28 Apr 2016

UBS, MPM team up on $471 million cancer fund to speed drug development

(Corrects minimum commitment to $200,000 from $500,000 figure given by UBS on Wednesday)

28 Apr 2016

OFFICIAL CORRECTION-UBS, MPM team up on $471 mln cancer fund to speed drug development

ZURICH, April 27 A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights.

28 Apr 2016

UPDATE 1-U.S. lawmakers want health agencies to lower prostate cancer drug cost

March 28 A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.

29 Mar 2016

BRIEF-Astellas Pharma Inc initiates pivotal phase III trial of Enzalutamide

* Pivotal phase III trial of Enzalutamide initiated in Metastatic Hormone Sensitive Prostate Cancer Source text for Eikon: Further company coverage:

24 Mar 2016

BRIEF-UK's CMA says not to refer Leo Pharma deal to buy Astellas Pharma portfolio to investigation

* Decided not to refer anticipated acquisition by Leo Pharma of the portfolio of pharma dermatological products of Astellas Pharma to phase 2 investigation Source text for Eikon: Further company coverage:

11 Mar 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks